Certain genetic polymorphisms in VEGF or markers (EGLN3, EGF, and WNK1) have been associated with an increased risk of hypertension in patients treated with other antiangiogenic agents such as bevacizumab or sunitinib.24 The gene discussed is VEGFA; the disease is Hypertension.